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Abstract
Prior research has demonstrated the reliability and validity of the Neurological
Predictor Scale (NPS) in relation to childhood brain tumor survivor outcomes; however,
its use has not been examined in adult long-term survivors. The current study examines
the concurrent validity of the NPS with long-term intellectual and adaptive outcomes in
adult survivors of childhood brain tumors relative to individual variables alone. A total of
68 adult survivors of childhood brain tumors (M=24 years old, SD=4) almost 16 years
post diagnosis (SD=6) completed intellectual evaluations using the Wechsler
Abbreviated Scale of Intelligence (WASI). Survivors’ adaptive functioning skills were
assessed via informant structured clinical interviews (SIB-R). NPS scores were
computed from data acquired from medical records. The NPS was significantly
associated with intellectual (R2=0.208, p< .05) and adaptive outcomes (R2= 0.30, p<
.05) over and above individual risk factors. Approximately 18% of long-term survivors
were identified as impaired in intellectual outcomes, and 29% were identified as
impaired in adaptive functioning in everyday life skills. The NPS quantifies the
cumulative effects of treatment and neurological sequelae experienced by both short
and long-term survivors of childhood brain tumors. It is a useful and easy measure to
employ in clinical research that focuses on quantifying the neurological risk factors
associated with long-term intellectual and adaptive functioning outcomes in adult
survivors of childhood brain tumors.
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Cumulative Neurological Factors Associated with Long-term Outcomes in Adult
Survivors of Childhood Brain Tumors

Introduction
Modern multifaceted treatment regimens for childhood brain tumors have
resulted in improved five-year survival rates (Ries, 2004) and a growing number of longterm survivors such that the majority of children diagnosed with brain tumors are now
surviving into adulthood (Gurney et al., 2003). However, the risks for poor long-term
outcomes are substantial, especially in those survivors treated aggressively and at a
young age (Ellenberg et al., 2009; Mulhern, Merchant, Gajjar, Reddick, & Kun, 2004).
Studies have documented lower or suboptimal intellectual and adaptive outcomes in
pediatric brain tumor survivors compared to their healthy peers (Beebe et al., 2005;
Papazoglou, King, Morris, & Krawiecki, 2008). Longitudinal studies have reported that
these children are acquiring intellectual and adaptive skills at a slower rate relative to
their same age peers but are not losing skills over time (Netson, Conklin, Wu, Xiong, &
Merchant, 2013; Palmer et al., 2001). By the time individuals are reaching adulthood,
there are increased demands on and expectations of rapid development of cognitive
abilities and independent living skills, but young adult survivors may experience more
significant impairments relative to peers who are gaining these skills. Poor adult
outcomes and neurocognitive impairment have primarily been documented via surveybased research by the Childhood Cancer Survivor Study (Ellenberg et al., 2009).
Therefore, it is critical to better understand the neurological factors associated with long-
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term intellectual performance and adaptive outcomes in adult survivors of childhood
brain tumors.
The research literature on long-term outcomes in adult survivors of brain tumors
has identified numerous treatment factors and health risks that are associated with poor
outcomes. Of these, radiation therapy is the most commonly reported predictor of poor
outcomes, and this finding has been supported through a number of studies using
various methodologies (e.g., radiation type, location, dose, age at radiation, time since
radiation: (Armstrong et al., 2010; Armstrong et al., 2009; Mulhern, Hancock,
Fairclough, & Kun, 1992). Often a proportion of participants are administered radiation
concurrently with chemotherapy as together these treatments contribute to increased
survival, albeit with negative cognitive and adaptive outcomes. In addition, other factors
such as hydrocephalus, seizures, and endocrine dysfunction have also been shown to
contribute to late effects described in survivors (Anderson, 2003; Ater et al., 1996;
Bruininks, Woodcock, Weatherman, & Hill, 1996; Duffner, 2004, 2010; Hardy, Bonner,
Willard, Watral, & Gururangan, 2008; King et al., 2004; Ris & Noll, 1994). These
common neurological factors that influence outcomes are numerous, interactive and
cumulative (Micklewright, King, Morris, & Krawiecki, 2008; Roman & Sperduto, 1995).
In a field with traditionally more limited sample sizes (Mulhern, Carpentieri,
Shema, Stone, & Fairclough, 1993; Ris & Noll, 1994), examining these potential
confounding and interrelated variables is complex and challenging. Ideally, clinical
research would be able to employ multivariate modeling approaches to address the
interactions between these important factors. However, the examination of multivariate
interactions requires a sizeable sample in order to have enough power to detect
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significance, and smaller samples may present misleading results if interactions are not
significant due to inadequate power and small effects. Similarly, in research designs
when a large homogenous sample across each of these factors is not possible,
examining the cumulative nature of the factors may help elucidate important
contributions to outcomes. Although it is not as direct as examining multivariate
interaction, it is important to consider not only the relation of each potential contributor
to outcomes but also the cumulative neuro-oncology risk factors that are associated
with the long-term outcomes of survivors of childhood brain tumors.
The Neurological Predictor Scale (NPS) provides researchers the ability to
quantify the cumulative effects of tumor and treatment-related conditions (Micklewright
et al., 2008). This measure takes into account the multiple treatments or neurological
sequelae which the individual may have experienced. Studies have documented the
reliability and concurrent validity in childhood survivors (Micklewright et al., 2008;
Papazoglou, King, Morris, & Krawiecki, 2009), but its concurrent validity has not yet
been examined in adult survivors of childhood brain tumors. The current study aims to
examine the concurrent validity of the NPS in adult survivors of childhood brain tumors.
Methods
Participants and Procedures
The study was reviewed and approved by the local institutional review boards,
and all participants provided informed consent. Adult survivors were recruited through
three different methods. First, adults who had been treated for a pediatric brain tumor at
Children’s Healthcare of Atlanta were identified. Second, survivors who had previously
been part of a childhood brain tumor study were identified. Based on these two lists, a
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total of 676 letters were mailed; of these, 88 letters were returned due to an incorrect
address. Finally, the Brain Tumor Foundation of Georgia ran an advertisement in their
annual newsletter requesting participation in this study, which prompted other survivors
to call to volunteer to participate in the study. Participants were excluded if English was
not their first language, if they met criteria for pervasive developmental disorders, if they
indicated a diagnosis of neurofibromatosis, or if they had experienced a traumatic brain
injury (TBI). Notably, the sample included one participant who had experienced a
stroke and five individuals who experienced posterior fossa syndrome following surgery.
As these complications may contribute important neurological information associated
with long-term outcomes, we did not exclude these individuals from the sample.
However, to ensure that these individuals were not solely contributing to the results, the
statistical analyses were rerun without these six individuals, and the results did not
appreciably change. Therefore, the results presented include survivors who have
experienced posterior fossa syndrome, as well as one person who has had a stroke. All
participants were over the age of 18 and were at least five years past their most recent
diagnosis in order to assess the effects of long-term survivorship.
Information about the brain tumor, subsequent treatments, and related
neurological risk factors were obtained from a retrospective medical records review. We
requested and reviewed physical medical records for all individuals who had been
treated for their brain tumor before 2002 at Children’s Healthcare of Atlanta. All medical
encounters after 2002 were reviewed through an electronic health record software. For
each participant in our study, we obtained information regarding tumor type (based on
histology lab reports), tumor location (based on notes from the surgeon who had
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excised the tumor and MRI scan notes from radiologists) and all subsequent treatments
(e.g. protocol numbers, type and dosage of radiation, chemotherapy, medications, type
of surgery and dates surrounding these treatments). We also gathered information
about comorbid neurological factors such as seizures, types of seizure medications,
presence and types of hormone deficiency, presence of hydrocephalus and ensuing
treatments for hydrocephalus. Data extraction agreement was 98% between raters. All
discrepancies were discussed between the raters and resolved before being single- and
double- entered into a database.
Overall, 68 participants were included in the analysis. The sample included 39
females and 29 males. Participants in the sample were between 18 and 35 years old,
with an average age of 23.78 years (SD = 4.43). Additionally, participants were an
average of 15.8 years post diagnosis (SD = 6.13). Tumor locations and tumor types
were heterogeneous. About half of the sample was diagnosed with either
medulloblastomas (29%) or juvenile pilocytic astrocytomas (22%); the remainder of the
sample was diagnosed with one of 15 different types of brain tumors (See Table I).
Brain tumor locations were also varied; the most common location for brain tumors was
the posterior fossa (62%), followed by the cerebral hemispheres (24%). For a complete
list of the characteristics of the sample, including but not limited to brain tumor type,
location, and treatment variables, refer to Table I.

Measures
Wechsler Abbreviated Scale of Intelligence (WASI)
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The WASI is a nationally standardized abbreviated measure of intelligence
comprised of four subtests. The measure has been shown to be reliable and valid, with
high correlations with other established intelligence measures (Wechsler, 1999).
Administration of all four subtests of this measure yields three indices: a verbal
intelligence score (measuring expressive vocabulary, verbal knowledge and abstract
verbal reasoning ability), a perceptual intelligence score (measuring spatial
visualization, visual-motor coordination and nonverbal fluid reasoning), and an overall
intellectual functioning score.

Scales of Independent Behavior - Revised (SIB-R)
The SIB-R is a norm-referenced assessment of adaptive and maladaptive
behavior in school, home, employment, and community settings. Informants were
interviewed by a trained graduate research assistant face-to-face. Informants were 82%
parents, 9% spouse/partner, 3% grandparents/legal guardian, 3% siblings and 3%
friends/roommates. Administration of this measure yields estimates of motor skills,
social interaction/communication skills, personal living skills, community living skills, and
broad independent living skills. These indices have demonstrated good reliability and
validity in a number of populations (Bruininks et al., 1996).

Neurological Predictor Scale (NPS)
The NPS is a brief measure that incorporates tumor, tumor treatment, and other
related neurological risk factors into one score. Prior to completing the NPS, two
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independent graduate students extracted information regarding treatments and
commonly associated neurological risk factors from medical records.
These conditions and treatments were further coded into a corresponding
number based on the NPS. As the items on the scale are objective ratings of
treatments (i.e., presence or absence of treatments and conditions that are clearly and
easily captured with a thorough medical records review) and subscores for each item on
the scale are summed through a computer program, there was high agreement among
raters (100%). The measure has been validated with a small sample of child survivors
of childhood brain tumors (Micklewright et al., 2008), and the purpose of the present
study is to examine the concurrent validity of the scale in a larger sample of adult
survivors of childhood brain tumors.

Data Analysis
First, we conducted a series of simple linear regression analyses. In these
analyses, the NPS score was the independent variable, while intelligence measures
(i.e., intellectual performance: verbal intelligence, perceptual intelligence) and adaptive
functioning skill measures (i.e., broad independent living skills, motor skills, social
communication skills, personal living skills and community living skills) were the
dependent variables. This step was designed to ensure that the variance in NPS scores
was significantly associated with the variance in the outcome measures in adult
survivors of pediatric brain tumors.
Second, we conducted a series of hierarchical regression analyses to ascertain
that the NPS score explains an additional amount of variance in two of the outcome
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measures (i.e., intellectual ability as indicated by the WASI and broad independent
living skills) above and beyond the variance already explained by any individual factor.
Individual treatment- or illness-related factors examined included type of radiation (i.e.,
no radiation, focal, whole brain, and whole brain with focal boost), presence of
chemotherapy, presence of neurosurgery, presence of hydrocephalus, presence of
hormone deficiency, and presence of seizure medications.

Results
A series of simple linear regression analyses indicated that the NPS scores were
significantly associated with all of the dependent variables of interest. Specifically, the
NPS scores were associated with intellectual performance, β = -0.46, t(66) = -4.16, p <
.001, and 20.8% of the variance for intellectual ability (R2 = 0.208, F(1,66)=17.33, p <
.01). The NPS scores also were also significantly associated with the participants’
verbal intelligence scores, β = -0.40, t(66) = -3.52, p <.001, and perceptual intelligence
scores, β = -0.45, t(66) = -4.11, p < .001. The NPS scores were associated with 15.8%
of the variance for verbal intelligence (R2 = 0.158, F(1,66)=12.42, p < .01) and 20.4% of
the variance for perceptual intelligence scores (R2 = 0.204, F(1,66)=16.92, p < .01).
The NPS scores were significantly associated with broad independent living
skills, β = -0.55, t(66) = -5.3, p < .001, and accounted for 30% of the variance in broad
independent living skills (R2 = 0.30, F(1,66)=28.10, p < .001). The NPS scores were
significantly associated with each of the component scores for adaptive functioning
skills: motor ability (β = -0.55, t(66) = -5.3, p < .001), social communication skills (β = 0.483, t(66) = -4.48, p < .001), personal living skills (β = -0.47, t(66) = -4.32, p < .001)
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and community living skills (β = -0.49, t(66) = -4.60, p < .001). The NPS scores were
also associated with between 22% and 36% of the variance of the SIB-R subscale
scores (see Table II for specific values). In sum, the NPS was significantly associated
with our dependent variables of interest: verbal intelligence, perceptual intelligence and
adaptive functioning skills.
A series of hierarchical multiple regression analyses were conducted to evaluate
whether the NPS scores accounted for a significant amount of variance above and
beyond the contributions of individual treatment and illness-related variables (i.e.,
radiation, chemotherapy, neurosurgery, hydrocephalus, hormone deficiencies and
seizure medications). The results indicated that the NPS scores accounted for a
significant amount of the variance in overall intellectual functioning after controlling for
the type of radiation (R2∆ = 0.076, p < 0.05), presence of chemotherapy (R2∆ = 0.137, p
< .05), presence of neurosurgery (R2∆ = 0.222, p < .05), presence of hydrocephalus
(R2∆ = 0.166, p < .05), presence of hormone deficiencies (R2∆ = 0.185, p < .05) and
presence of seizure medications (R2∆ = 0.208, p < .05). Similarly, the NPS scores
accounted for a significant amount of the variance in broad independent living skills
after controlling for individually examined treatment- and illness-related variables,
including type of radiation (R2∆ = 0.098, p < .05), presence of chemotherapy (R2∆ =
0.161, p < .05), presence of neurosurgery (R2∆ = 0.309, p < .05), presence of
hydrocephalus (R2∆ = 0.276, p < .05), presence of hormone deficiencies (R2∆ = 0.232,
p < .05) and presence of seizure medications (R2∆ = 0.298, p < .05). Table III displays
additional details regarding each step of the hierarchical regressions and the change in
adjusted R2 associated with each step, as well as the standardized coefficients
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associated with each independent variable in the models. These analyses show that
NPS scores were associated with intellectual and adaptive outcomes above and beyond
each individual treatment or neurological risk factor.
In order to capture the diverse nature of the impact of treatments and tumor
sequelae on outcomes, the inclusion of a heterogeneous tumor group was important for
this study. Patients with rare diagnoses or other complicating conditions (stroke,
posterior fossa syndrome) were examined in order to ensure that these participants
were not appreciably influencing the association that we found between NPS scores
and our dependent variables of interest. Examination of the scatterplots ensured that
none of these rare cases were outliers. After removing the rare tumor cases and
patients with complicating conditions (stroke, posterior fossa syndrome) from the
analyses, the strength and directionality of the results did not appreciably change.

Discussion
The present study demonstrates that the NPS is more associated with intellectual
and adaptive outcomes of childhood brain tumor survivors on average over 15 years
post diagnosis than each independently examined individual treatment or neurological
risk factor. The proportion of variance that the NPS accounted for ranged from 16 to
36% with medium-to-large effect sizes (0.4-0.6). These findings are consistent with past
NPS studies on childhood brain tumor survivors (Micklewright et al., 2008; Papazoglou
et al., 2009) suggesting that the NPS is a more robust measure of the complexity of
neurological risk factors compared to one risk factor alone and that the NPS affords
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studies great power in detecting the role of cumulative neurological factors in long-term
cognitive and adaptive outcomes.
The current findings also are consistent with previous literature on treatments
(chemotherapy, radiation, neurosurgery) and neurological sequelae (hydrocephalus,
seizure, and endocrine) (Anderson, 2003; Armstrong et al., 2009; Ater et al., 1996;
Bruininks et al., 1996; Duffner, 2004, 2010; Hardy et al., 2008; King et al., 2004;
Mulhern et al., 1992; Ris & Noll, 1994; Roman & Sperduto, 1995) being strongly
associated with survivor outcomes. However, the current study demonstrates that the
NPS is better than any one factor alone, as it takes into account the complexity and
cumulative nature of neurological complications that are related to long-term outcomes
in childhood brain tumor survivors.
Interestingly, survivors on average performed similar to peers on the WASI but a
wide range of outcomes were evidenced. Indeed, 17.6% of the survivors were impaired
on the intelligence measure (z ≤ -1.5). Similarly, adaptive outcomes were within normal
limits on average but spanned an extremely wide range, and 29% of the sample was
identified as impaired in the areas of adaptive functioning and day to day living skills on
the SIB-R. The SIB-R is a structured clinical interview with informants who know the
survivor well and observe him or her engaging in daily activities. This measure was
even more robustly related to the NPS and identified a larger number of more
significantly impaired survivors. This suggests that in spite of average intellectual
performance, a sizeable proportion (29%) of survivors is impaired in terms of everyday
life skills. Furthermore, as neurological complications increase, it is more likely that
impaired ability will be found in everyday function, which increases dependence on
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others. These findings are particularly important with young adult survivors whose peers
are completing college or advanced education, securing employment or careers,
developing and maintaining friendships and partners, and negotiating leisure activities in
the community.
A greater proportion of impaired adaptive living skills may be related to another
variable or variables, such as one or more impaired core cognitive skills. Disruption of
core cognitive skills such as processing speed, attention, and/or working memory are
commonly reported in the literature (Palmer, 2008; Reddick et al., 2003; Wolfe, MadanSwain, & Kana, 2012) and may be better captured by the adaptive functioning skills in
the SIB-R compared to the WASI. We specifically selected the WASI for the IQ measure
so that these core cognitive skills would be less likely to depress estimates of global
cognitive ability. Therefore the possibility of the NPS demonstrating concurrent validity
with core cognitive skills should be examined in the future. In addition, these findings
further support the benefit of obtaining complementary information about survivorship
outcomes with both cognitive performance and informant report of everyday abilities.
It is important to note that treatment intensity has been examined to some extent
in existing research literature. In these studies, the intensity variable is generally defined
(in order from least to most intense) as stepwise groups of siblings, patients with acute
lymphoblastic leukemia (ALL), patients with typical radiation with or without
chemotherapy, and patients with a higher level of radiation with or without
chemotherapy. However, modeling and measuring treatment intensity in this manner
may not always be appropriate. Depending on the specific research question, how one
quantifies treatment intensity or risk/prognostic factors is important. One could argue
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that a cumulative scale that takes into account factors common to brain tumor patients
is superior to comparing across disease (e.g., ALL, brain tumor, and other cancer). For
example, brain tumor patients share some extent of neurosurgery (subtotal, gross total,
biopsy), hydrocephalus, or seizure medication. However, when comparing a radiation
group to a no radiation group, participants may also differ on whether they received
chemotherapy or if they had neuroendocrine involvement. Simply reporting that the
findings are due to the neurotoxic effects of radiation may be misleading.
Acknowledging co-occurring factors and potential confounds as well as quantifying the
cumulative nature of these differences as the NPS scores do may advance research in
the field.
The NPS may be used as a tool for further examining research findings and
parsing apart how treatment complexities relate to main research findings. For example,
across radiation and no-radiation groups, one may examine how NPS scores or
increased cumulative neurological risk are related to later reduced adaptive functioning
(Papazoglou et al., 2009). The initial paper on the NPS (Micklewright et al., 2008)
demonstrated concurrent validity in 25 short-term childhood brain tumor survivors with
the NPS and IQ. Our research team also demonstrated that the NPS and parent report
of attention problems was associated with later adaptive functioning in 42 children
treated for brain tumors (Papazoglou et al., 2009). Another research team has recently
demonstrated concurrent validity in an independent sample of 82 childhood brain tumor
survivors on average 2.4 years since treatment, with the NPS and intellectual outcome
(McCurdy, Rane, Daly, Jacobson, 2014). Similarly, another study examined an
independent sample of 75 childhood brain tumor survivors on average 2.5 years since
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treatment, and found that poorer processing speed and working memory outcomes
were associated with the NPS (McCurdy, 2014). In addition, our research team recently
demonstrated that the NPS was specifically related to hippocampal and putamen
volume but not associated with whole brain volume in 35 adult survivors of childhood
brain tumors (Jayakar, King, Morris, & Na, 2015). NPS findings such as these help to
promote ideas for future larger scale research studies and expand the focus of research
beyond radiation treatment alone. Although radiation treatment is a critical factor in
outcome research, it may be misleading if complementary analyses of neurological
complexity are not also considered. Therefore, the NPS appears to be associated with
outcomes across different types of measurement without shared method variance,
suggesting strong concurrent validity in both child and adult survivors of childhood brain
tumors.
The current study should be considered in the context of its limitations.
Participants were recruited through different mechanisms (e.g., letters and newsletters)
making it difficult to know the true source population. Therefore, there may be selection
bias in those participants who contacted the research team to participate in the study. It
may be that the survivors who wanted to participate were more impaired and wanted
more health care provider contact. It is equally possible, in this convenience sample,
that the survivors who wanted to participate were more able to given higher cognitive or
adaptive functioning skills. Another limitation that should be considered is that the
survivors in this study were treated between 1979 and 2008 and therefore are unlikely
to reflect the most recent treatment advances being implemented. That said, the
growing number of survivors requires multidisciplinary teams in order to continue
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considering the role of these cumulative risk factors from older treatment practices in
long-term outcomes. It also is recognized that some study designs may have a precise
question about the role of radiation dosages to specific brain areas in specific diagnostic
groups. In this situation, highly homogenous diagnostic and radiation treatment data is
necessary. However, to rule out other potential confounds that may be concurrently
contributing to the outcomes observed in that hypothetical homogenous group,
researchers may consider using the NPS to quantify other complex medical factors that
may differ between participants and identify how much additional variance these related
factors may also contribute. While the NPS is not able to contribute to specific
hypotheses that require a refined measurement strategy such as dosimetry or integral
biologically effective dose (IBED:(Ris, 2007) when examining the impact of radiation on
cognitive outcome, it may provide complementary information in the same study about
the association between the cumulative risk and outcomes, indicating the other
potentially important co-occurring complications. Therefore, the NPS has the potential to
contribute to our knowledge of complex risk factors in survivors of childhood brain
tumors. Future prospective longitudinal studies with larger samples may consider
exploring if the cumulative NPS scale adds complementary information to multivariate
analyses.
In any location in the world, the sample size of children undergoing treatment for
brain tumor is fortunately not large. In order to capture the multiple potential
complications a survivor may experience, a cumulative measure such as the NPS may
be the easiest to implement. The NPS as it is currently designed is not able to examine
the interactions that may exist between individual treatment factors, but it is certainly a
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first step toward examining neurological complexity within brain tumor samples above
and beyond simple descriptive reports of each variable.
In summary, the current study demonstrates the concurrent validity between the
NPS and intellectual and adaptive functioning measures. Based on these results, the
NPS may be an informative clinical research tool especially in studies with
heterogeneous brain tumor samples. Notably, the NPS is very user-friendly; the scale is
clear, straightforward and efficient to complete after obtaining thorough medical record
review information. Future research could examine the role of these factors when
examining neurobiological variables (e.g., white matter volume and microstructure),
core cognitive (e.g., processing speed, attention and working memory) and
psychosocial outcomes, quality of life, and other factors critical to improving long-term
cancer survivorship.
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Table I. Demographic, Diagnostic and Treatment Variables.
Variables
Demographic Variables
Female (n, %)
Hollingshead socio-economic status (mean ± SD)
Age at testing (mean ± SD)
Range
Ethnicity (n, %)
Caucasian
African-American
Other
Employment status (n, %)
Student
Employed
Unemployed
Disability
Diagnostic Variables
Years post diagnosis (mean ± SD)
Range
Age at diagnosis (mean ± SD)
Range
Tumor location (n, %)
Posterior fossa
Cerebral hemispheres
Ventricles
Pituitary
Brain stem
Tumor type (n, %)
Medulloblastoma
Juvenile pilocytic astrocytoma
Diffuse astrocytoma
Craniopharyngioma
Ganglioglioma
Ependymoma
Other†
Treatment Variables
Radiation (n, %)
Radiation type (n, %)
Focal
Whole brain

Survivors (n=68)
39 (57%)
2.2 ± 1.09
23.78 ± 4.43
18-35
55 (81%)
9 (13%)
4 (6%)
31 (46%)
22 (32%)
8 (12%)
7 (10%)
15.8 ± 6.13
5 – 28
7.96 ± 4.8
0 – 17
42 (62%)
16 (24%)
5 (7%)
3 (4%)
2 (3%)
20 (29%)
15 (22%)
6 (9%)
5 (7%)
3 (4%)
3 (4%)
16 (25%)
35 (52%)
8 (23%)
4 (11%)
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Craniospinal with boost
23 (66%)
Chemotherapy (n, %)
25 (37%)
Neurosurgery
67 (99%)
Hydrocephalus (n, %)
46 (68%)
Seizure Medication (n, %)
18 (27%)
Hormone deficiency (n, %)
33 (49%)
Hormone deficiency type (n, %)
Hypothyroidism
22 (32%)
Growth hormone deficiency
15 (22%)
Hypogonadism
6 (9%)
Hypoadrenalism
5 (7%)
Measures
Full scale IQ (mean ± SD)
95.53 ± 18.79
54 – 128
Range
17.6 %
% impaired (≤-1.5z)
Broad independent living skills standard score
(mean ± SD)
95.24 ± 28.98
Range
33 – 144
% impaired (≤-1.5z)
29.4 %
†
Note. Two oligodendroglioma, two brainstem glioma, two anaplastic astrocytoma, two
cerebral neuroblastoma, two mixed astrocytoma/ganglioglioma, one malignant
melanoma, one pineoblastoma, one meningioma, one germ cell tumor, one
medulloepithelioma, one non-infiltrative mesenchymal neoplasm, not otherwise
specified.

Table II. Simple Linear Regression Models of the Predictive Relationship Between NPS
and Various Dependent Variables of Interest (n=68)
Measure
Full Scale IQ
Verbal IQ
Perceptual IQ
Broad Independent Living
Skills
Motor Skills
Social Communication Skills
Personal Living Skills
Community Living Skills
Note. *p < .05, ** p < .01

B
-3.81
-3.08
-3.76
-7.04

SE B
0.92
0.87
0.91
1.33

β
-.46
-.40
-.45
-.55

t
-4.16
-3.52
-4.11
-5.30

p
<.001**
.001**
<.001**
<.001**

-8.85
-4.93
-4.69
-5.42

1.44
1.10
1.09
1.18

-.60
-.48
-.47
-.49

-6.15
-4.48
-4.32
-4.60

<.001**
<.001**
<.001**
<.001**
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Table III Hierarchical Regression Models Relating Intelligence and Broad Independent
Living Skills to Treatment Related Factors and NPS Scores (N=68)
Intellectual Functioning
Broad Independent Living
Skills
Individual Treatment Factor
Radiation
Model 1
Type of Radiation
Model 2
Type of Radiation
NPS Score
Chemotherapy
Model 1
Presence of Chemotherapy
Model 2
Presence of Chemotherapy
NPS Score
Neurosurgery
Model 1
Presence of Neurosurgery
Model 2
Presence of Neurosurgery
NPS Score
Hydrocephalus
Model 1
Presence of Hydrocephalus
Model 2
Presence of Hydrocephalus
NPS Score
Hormone Deficiencies
Model 1
Presence of Hormone Deficiencies
Model 2
Presence of Hormone Deficiencies
NPS Score
Seizure Medication
Model 1
Presence of Seizure Medications
Model 2
Presence of Seizure Medications
NPS Score

Adjusted
R2

∆ R2

.12

.13

β

Adjusted
R2

∆ R2

.18

.19

-.36**
.18

.08

-.44**
.27

.10

.07
-.51*
.07

.08

.05
-.58**
.13

.14

-.29*
.20

.14

-.38**
.28

.16

.18
.593**
-.02

.0

.20

.22

.12
-.64**

-.015

.0

.29

.31

.017

-.02

.12
-.48**
.04

.05

.20

.17

.11
-.57**
.01

.02

.28

.28

-.23

-.15

-.11
-.42**
-.003

.012

.22

.23

-.114

β

.002
-.55**
.10

.11

.28

.19

-.34**
.23
-.59**
.0

-.02

.18

.21

-.04
-.53**
-.02

.0

.28

.30

-.017

-.02

-.006
-.46**

Note. *p < .05, ** p < .01 All beta values for NPS scores in the second models for both dependent variables were significant. This
finding indicates that NPS continues to predict intellectual and adaptive outcomes after controlling for individual risk factors.

-.007
-.55**

